Rogelio García-Centeno

Rogelio García-Centeno

Auto-generated profile, based on publicly available information

Rogelio García-Centeno

Endocrinology & Nutrition Department, Hospital Universitario Gregorio Marañón, 28007 Madrid, Spain

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Marta Araujo-CastroMarta Araujo-Castro
Marta Araujo-Castro
RGRogelio García-Centeno
Rogelio García-Centeno
LGLaura González
Laura González
FHFelicia Alexandra Hanzu
Felicia Alexandra Hanzu
AAAida Orois Anon
Aida Orois Anon
ASAlfonso Soto-Moreno
Alfonso Soto-Moreno
Objective: To evaluate the efficacy and safety of osilodrostat in patients with Cushing’s disease (CD). Methods: A retrospective, multicenter, real-world study of patients with CD. The main efficacy endpoint was the proportion of patients who were complete responders (urinary free cortisol [UFC] < the upper limit of normal and/or with adrenal insufficiency development). Results: Thirty-seven CD patients were enrolled. There were 33 patients who initially received osilodrostat in monotherapy and 4 in combination. However, 3 patients of the monotherapy group were switched to combination therapy. The median duration of osilodrostat treatment was 5 months (range 1–93). All the patients were classified as responders: 33 (89.2%) had complete response and 4 partial response. A positive correlation was detected between the percentage of UFC decrease and the maximum (r = 0.481, p = 0.006) and the maintenance doses (r = 0.440, p = 0.011). The initial doses of osilodrostat were a predictor of complete response (vs. partial) (Odds ratio [OR] 2.82, p = 0.030). The median time to UFC normalization in the group of complete responders was 4 weeks (range 1–20) and UFC normalized before or at month 1 in 67% (n = 20/30) of the patients. Osilodrostat led to a significant decrease in systolic and diastolic blood pressure in parallel with a reduction of antihypertensive medications. Conclusions: Osilodrostat leads to a complete UFC normalization in up to 90% of the patients with CD, in parallel with an improvement in the cardiometabolic profile. A proper titration of osilodrostat is important to achieve a complete response since a positive correlation between the doses and the UFC reduction was observed.

1 October 2009 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
PDF file
RGRogelio García-Centeno
Rogelio García-Centeno
JSJosé Pablo Suárez-Llanos
José Pablo Suárez-Llanos
EFElisa Fernández-Fernández
Elisa Fernández-Fernández
VAVictor Andía-Melero
Victor Andía-Melero
PSPetra Sánchez
Petra Sánchez
AJAntonino Jara-Albarrán
Antonino Jara-Albarrán

23 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Marta Araujo-CastroMarta Araujo-Castro
Marta Araujo-Castro
IGIñigo Q García-Sanz
Iñigo Q García-Sanz
COCésar Mínguez Ojeda
César Mínguez Ojeda
MGMaria Calatayud Gutierrez
Maria Calatayud Gutierrez
FHFelicia Alexandra Hanzu
Felicia Alexandra Hanzu
AHAura D. Herrera-Martinez
Aura D. Herrera-Martinez
Purpose: to perform an external validation of our predictive model to rule out pheochromocytoma (PHEO) based on unenhanced CT in a cohort of patients with PHEOs and adenomas who underwent adrenalectomy. Methods: The predictive model was previously developed in a retrospective cohort of 1131 patients presenting with adrenal lesions. In the present study, we performed an external validation of the model in another cohort of 214 patients with available histopathological results. Results: For the external validation, 115 patients with PHEOs and 99 with adenomas were included. Our previously described predictive model combining the variables of high lipid content and tumor size in unenhanced CT (AUC-ROC: 0.961) had a lower diagnostic accuracy in our current study population for the prediction of PHEO (AUC: 0.750). However, when we excluded atypical adenomas (with Hounsfield units (HU) > 10, n = 39), the diagnostic accuracy increased to 87.4%. In addition, in the whole cohort (including atypical adenomas), when MRI information was included in the model, the diagnostic accuracy increased to up to 85% when the variables tumor size, high lipid content in an unenhanced CT scan, and hyperintensity in the T2 sequence in MRI were included. The probability of PHEO was <0.3% for adrenal lesions 10 HU and without hyperintensity in T2. Conclusion: Our study confirms that our predictive model combining tumor size and lipid content has high reliability for the prediction of PHEO when atypical adrenal lesions are excluded. However, for atypical adrenal lesions with >10 HU in an unenhanced CT scan, MRI information is necessary for a proper exclusion of the PHEO diagnosis.